PMID- 26340939
OWN - NLM
STAT- MEDLINE
DCOM- 20160321
LR  - 20181202
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 191
IP  - 12
DP  - 2015 Dec
TI  - Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade 
      gliomas.
PG  - 945-52
LID - 10.1007/s00066-015-0888-1 [doi]
AB  - BACKGROUND: In 20 patients with high-grade gliomas, we compared two methods of 
      planning for volumetric-modulated arc therapy (VMAT): simultaneous integrated 
      boost (SIB) vs. sequential boost (SEB). The investigation focused on the analysis 
      of dose distributions in the target volumes and the organs at risk (OARs). 
      METHOD: After contouring the target volumes [planning target volumes (PTVs) and 
      boost volumes (BVs)] and OARs, SIB planning and SEB planning were performed. The 
      SEB method consisted of two plans: in the first plan the PTV received 50 Gy in 25 
      fractions with a 2-Gy dose per fraction. In the second plan the BV received 10 Gy 
      in 5 fractions with a dose per fraction of 2 Gy. The doses of both plans were 
      summed up to show the total doses delivered. In the SIB method the PTV received 
      54 Gy in 30 fractions with a dose per fraction of 1.8 Gy, while the BV received 
      60 Gy in the same fraction number but with a dose per fraction of 2 Gy. RESULTS: 
      All of the OARs showed higher doses (Dmax and Dmean) in the SEB method when 
      compared with the SIB technique. The differences between the two methods were 
      statistically significant in almost all of the OARs. Analysing the total doses of 
      the target volumes we found dose distributions with similar homogeneities and 
      comparable total doses. CONCLUSION: Our analysis shows that the SIB method offers 
      advantages over the SEB method in terms of sparing OARs.
FAU - Farzin, Mostafa
AU  - Farzin M
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische 
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany. 
      mfarzin1355@yahoo.com.
AD  - Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran 
      University of Medical Science, Tehran, Iran. mfarzin1355@yahoo.com.
FAU - Molls, Michael
AU  - Molls M
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische 
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany. 
      michael.molls@lrz.tum.de.
FAU - Astner, Sabrina
AU  - Astner S
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische 
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany. 
      Sabrina.Astner@gmx.de.
FAU - Rondak, Ina-Christine
AU  - Rondak IC
AD  - Institut fur Medizinische Statistik und Epidemiologie, Klinikum rechts der Isar, 
      Technische Universitat Munchen, Munich, Germany. ina.rondak@tum.de.
FAU - Oechsner, Markus
AU  - Oechsner M
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische 
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany. 
      markus.oechsner@lrz.tu-muenchen.de.
LA  - eng
PT  - Clinical Study
PT  - Comparative Study
PT  - Journal Article
DEP - 20150904
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Adult
MH  - Aged
MH  - Astrocytoma/pathology/*radiotherapy
MH  - Brain Neoplasms/pathology/*radiotherapy
MH  - Combined Modality Therapy
MH  - *Dose Fractionation, Radiation
MH  - Female
MH  - Glioblastoma/pathology/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Organs at Risk/radiation effects
MH  - Radiation Injuries/prevention & control
MH  - Radiotherapy Dosage
MH  - *Radiotherapy Planning, Computer-Assisted
MH  - Radiotherapy, Adjuvant
MH  - Radiotherapy, Intensity-Modulated/*methods
OTO - NOTNLM
OT  - High-grade glioma
OT  - Organs at risk
OT  - Sequential boost
OT  - Simultaneous integrated boost
OT  - Volumetric-modulated arc therapy
EDAT- 2015/09/06 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/09/06 06:00
PHST- 2014/12/08 00:00 [received]
PHST- 2015/08/07 00:00 [accepted]
PHST- 2015/09/06 06:00 [entrez]
PHST- 2015/09/06 06:00 [pubmed]
PHST- 2016/03/22 06:00 [medline]
AID - 10.1007/s00066-015-0888-1 [pii]
AID - 10.1007/s00066-015-0888-1 [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2015 Dec;191(12):945-52. doi: 10.1007/s00066-015-0888-1. Epub 
      2015 Sep 4.